222 related articles for article (PubMed ID: 16173956)
1. Optimizing therapy for myeloid disorders of Down syndrome.
Webb DK
Br J Haematol; 2005 Oct; 131(1):3-7. PubMed ID: 16173956
[TBL] [Abstract][Full Text] [Related]
2. Acute leukaemia in children with Down syndrome: a population-based Nordic study.
Zeller B; Gustafsson G; Forestier E; Abrahamsson J; Clausen N; Heldrup J; Hovi L; Jonmundsson G; Lie SO; Glomstein A; Hasle H;
Br J Haematol; 2005 Mar; 128(6):797-804. PubMed ID: 15755283
[TBL] [Abstract][Full Text] [Related]
3. Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891.
Gamis AS; Woods WG; Alonzo TA; Buxton A; Lange B; Barnard DR; Gold S; Smith FO;
J Clin Oncol; 2003 Sep; 21(18):3415-22. PubMed ID: 12885836
[TBL] [Abstract][Full Text] [Related]
4. Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts.
Langebrake C; Creutzig U; Reinhardt D
Klin Padiatr; 2005; 217(3):126-34. PubMed ID: 15858703
[TBL] [Abstract][Full Text] [Related]
5. Optimal treatment intensity in children with Down syndrome and myeloid leukaemia: data from 56 children treated on NOPHO-AML protocols and a review of the literature.
Abildgaard L; Ellebaek E; Gustafsson G; Abrahamsson J; Hovi L; Jonmundsson G; Zeller B; Hasle H
Ann Hematol; 2006 May; 85(5):275-80. PubMed ID: 16518605
[TBL] [Abstract][Full Text] [Related]
6. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
Tomizawa D; Tabuchi K; Kinoshita A; Hanada R; Kigasawa H; Tsukimoto I; Tsuchida M;
Pediatr Blood Cancer; 2007 Aug; 49(2):127-32. PubMed ID: 16807916
[TBL] [Abstract][Full Text] [Related]
7. Acute myeloid leukemia and Down syndrome evolution of modern therapy--state of the art review.
Gamis AS
Pediatr Blood Cancer; 2005 Jan; 44(1):13-20. PubMed ID: 15534881
[TBL] [Abstract][Full Text] [Related]
8. Down syndrome, drug metabolism and chromosome 21.
Taub JW; Ge Y
Pediatr Blood Cancer; 2005 Jan; 44(1):33-9. PubMed ID: 15390307
[TBL] [Abstract][Full Text] [Related]
9. GATA1 mutations in acute leukemia in children with Down syndrome.
Magalhães IQ; Splendore A; Emerenciano M; Figueiredo A; Ferrari I; Pombo-de-Oliveira MS
Cancer Genet Cytogenet; 2006 Apr; 166(2):112-6. PubMed ID: 16631466
[TBL] [Abstract][Full Text] [Related]
10. Prospective study of a pirarubicin, intermediate-dose cytarabine, and etoposide regimen in children with Down syndrome and acute myeloid leukemia: the Japanese Childhood AML Cooperative Study Group.
Kudo K; Kojima S; Tabuchi K; Yabe H; Tawa A; Imaizumi M; Hanada R; Hamamoto K; Kobayashi R; Morimoto A; Nakayama H; Tsuchida M; Horibe K; Kigasawa H; Tsukimoto I;
J Clin Oncol; 2007 Dec; 25(34):5442-7. PubMed ID: 18048827
[TBL] [Abstract][Full Text] [Related]
11. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.
Creutzig U; Zimmermann M; Lehrnbecher T; Graf N; Hermann J; Niemeyer CM; Reiter A; Ritter J; Dworzak M; Stary J; Reinhardt D
J Clin Oncol; 2006 Sep; 24(27):4499-506. PubMed ID: 16983120
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy for myeloid malignancy in children with Fanconi anemia.
Mehta PA; Ileri T; Harris RE; Williams DA; Mo J; Smolarek T; Auerbach AD; Kelly P; Davies SM
Pediatr Blood Cancer; 2007 Jun; 48(7):668-72. PubMed ID: 16609946
[TBL] [Abstract][Full Text] [Related]
13. Myeloid leukaemia in children with Down syndrome: report of the registry-based French experience between 1990 and 2003.
Tandonnet J; Clavel J; Baruchel A; Nacka F; Pérel Y
Pediatr Blood Cancer; 2010 Jul; 54(7):927-33. PubMed ID: 20405513
[TBL] [Abstract][Full Text] [Related]
14. Acute leukemias in children with Down syndrome.
Zwaan MC; Reinhardt D; Hitzler J; Vyas P
Pediatr Clin North Am; 2008 Feb; 55(1):53-70, x. PubMed ID: 18242315
[TBL] [Abstract][Full Text] [Related]
15. Transient myeloproliferative syndrome/transient acute myeloid leukemia in a newborn with Down syndrome: a case report and literature review.
D'Angelo G; Merlo P
Lab Hematol; 2003; 9(1):38-41. PubMed ID: 12661826
[TBL] [Abstract][Full Text] [Related]
16. Transient leukemia (transient myeloproliferative disorder, transient abnormal myelopoiesis) of Down syndrome.
Brink DS
Adv Anat Pathol; 2006 Sep; 13(5):256-62. PubMed ID: 16998319
[TBL] [Abstract][Full Text] [Related]
17. Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials.
Rao A; Hills RK; Stiller C; Gibson BE; de Graaf SS; Hann IM; O'Marcaigh A; Wheatley K; Webb DK
Br J Haematol; 2006 Mar; 132(5):576-83. PubMed ID: 16445830
[TBL] [Abstract][Full Text] [Related]
18. Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891.
Lange BJ; Kobrinsky N; Barnard DR; Arthur DC; Buckley JD; Howells WB; Gold S; Sanders J; Neudorf S; Smith FO; Woods WG
Blood; 1998 Jan; 91(2):608-15. PubMed ID: 9427716
[TBL] [Abstract][Full Text] [Related]
19. PRAME immunohistochemical staining in transient abnormal myelopoiesis and myeloid leukemia associated with Down syndrome.
Chisholm KM; Rivetta CV; Heerema-McKenney A
Ann Clin Lab Sci; 2015; 45(2):121-7. PubMed ID: 25887863
[TBL] [Abstract][Full Text] [Related]
20. Down myeloid disorders: a paradigm for childhood preleukaemia and leukaemia and insights into normal megakaryopoiesis.
Vyas P; Roberts I
Early Hum Dev; 2006 Dec; 82(12):767-73. PubMed ID: 17064858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
